<DOC>
	<DOCNO>NCT01953510</DOCNO>
	<brief_summary>Pneumococcus group bacteria cause pneumonia , meningitis disease . These bacteria normally live nose human spread person person touch sneeze . There vaccine available protect infection bacteria , pneumococcus currently lead vaccine-preventable cause death young child . In country pneumococcal vaccine ( PCV ) introduce , big impact amount disease cause bacteria . However , many country , especially develop country , yet introduce PCV part routine immunization . Currently total four dos PCV recommend , main barrier vaccine introduction cost . This study aim identify vaccination schedule make PCV effective affordable Vietnam develop country . This study two distinct purpose : 1 ) compare different dosage schedule PCV 2 ) compare different PCV vaccine . 1 . Schedules Synflorix ( PCV10 ) involve three , two one dose PCV primary series two booster option compare . Comparisons make firstly term measure immunity vaccine , secondly term effect vaccination carriage bacteria nose . 2 . The response PCV10 Prevenar-13 ( PCV13 ) compare , schedule likely consider global use . Again , comparison make term measure immunity effect carriage nose . Infants age two month randomly assign one six study group provide four blood sample analysis measure immunity five nose swab analysis carriage bacteria . Infants follow 8-9 time age 24 month . An additional control group recruit 18 month age also follow 24 month age . The result study used facilitate decision making , global national level , regard introduction PCV .</brief_summary>
	<brief_title>Trial Pneumococcal Vaccine Schedules Ho Chi Minh City , Vietnam</brief_title>
	<detailed_description>Introduction The overall purpose study investigate simplify childhood vaccination schedule appropriate develop country use . This study specifically design address two independent question within single study : 1 . What optimal schedule provision EPI vaccine incorporation PCV10 ? Schedules involve three , two one dose PCV10 primary series evaluate , time around option simplification Expanded Programme Immunization ( EPI ) schedule develop country . A simplified schedule pneumococcal booster dose bring forward closer peak incidence disease likely increase compliance vaccine effectiveness . A booster nine month age coincide usual time administration measles vaccine , whereas booster six month age would provide early protection may enable abbreviated 1+1 pneumococcal vaccination schedule . 2 . How response PCV vaccination PCV10 PCV13 compare ? PCV10 PCV13 two PCVs available Advanced Market Commitment ( AMC ) mechanism , mechanism provide fund vaccine introduction develop country . However , study date directly compare two vaccine . Directly compare two vaccine provide useful information country consider introduction PCV . There important difference vaccine . PCV10 include ten pneumococcal serotypes PCV13 include thirteen . PCV10 use non-typeable Haemophilus influenzae ( NTHi ) Protein D carrier , may confer protection H. influenzae , PCV13 use CRM197 carrier . It interest know whether vaccine differ either immunogenicity impact nasopharyngeal ( NP ) carriage . Design Infants randomize one six study arm ( A-F ) . All infant participant receive four dos Infanrix-hexa ( DTaP-Hib-HBV-IPV ) least two dos PCV . The PCV schedule evaluate : 3+1 PCV10 schedule 2 , 3 , 4 9 month age ( Arm A ) ; 3+0 PCV10 schedule 2 , 3 4 month age ( Arm B ) ; 2+1 PCV10 schedule 2 , 4 9 month age ( Arm C ) ; 1+1 PCV10 schedule 2 6 month age ( Arm D ) ; 2+1 PCV13 schedule 2 , 4 9 month age ( Arm E ) . Arm F , control group , receive two dos PCV10 18 24 month age . An additional control group ( Arm G ) recruit 18 month age receive Infanrix-hexa 18 month age single dose PCV10 24 month age . Reactogenicity assess follow vaccination visit use diary card . Participants arm A-E provide six NP swabs analysis NP carriage outcome , 2 , 6 , 9 , 12 , 18 24 month age ; provide four blood sample course trial analysis vaccine response . Blood 1 take four week post-primary series ; Blood 2 take pre-booster ( arm A , C , D E ) 9 month age ( subset arm B ) ; Blood 3 take four week post-booster ( arm A , C , D E ) 10 month age ( arm B ) . An additional blood sample take : 18 month age subset arm A , B , C , D E ; 2 month age subset arm A ; 6 month age subset arm B C ; 9 month age subset arm D ; 3 month age subset arm E. Participants control arm provide NP swab 2 , 6 , 9 , 12 , 18 24 month age ( arm F ) 18 24 month age ( arm G ) , provide blood sample 18 ( Blood 4 ) , 19 ( Blood X ) 24 ( Blood Y ) month age . Objectives 1 . What optimal schedule provision EPI vaccine incorporation PCV10 ? The primary objective compare 2+1 schedule 2 , 4 9 month age 3+1 schedule 2 , 3 , 4 9 month age , primary outcome immunogenicity PCV10 , four week post-primary series ( Arm C v . Arm A+B ) . Secondary objective investigate experimental 1+1 schedule 2 6 month age ( Arm D v . Arm A+B Arm D v . Arm C ) , assess impact booster dose carriage ( Arm A v . Arm F Arm A v . Arm B ) . 2 . How response PCV vaccination PCV10 PCV13 compare ? The primary objective compare PCV13 schedule 2 , 4 9 month age PCV10 schedule 2 , 3 , 4 9 month age , primary outcome immunogenicity PCV , four week post-primary series ( Arm E v . Arm A+B ) . Secondary objective compare PCV13 schedule 2 , 4 9 month age PCV10 schedule 2 , 4 9 month age ( Arm E v . Arm C ) , compare response single dose PCV13 PCV10 ( Arm E v . Arm D ) . Other objective : examine decline pneumococcal antibody level time ( Arm B ) ; describe serotype profile transfer maternal pneumococcal antibody ( Arm A ) ; describe early rate carriage ( Arms A-F ) ; evaluate single dose PCV10 18 month age ( Arm F ) ; evaluate immunogenicity Infanrix-hexa 18 month age child receive three dos Infanrix-hexa three dos Quinvaxem ( DTwP-Hib-HBV ) infancy . Sample Size The propose infant sample size 1200 allocation ratio 3:3:5:4:5:4 , result arm size : A=150 , B=150 , C=250 , D=200 , E=250 , F=200 . Sample size calculation base primary outcome two study question : post-primary series immunogenicity compare 1 ) two dose ( Arm C ) three dose ( Arm A+B ) PCV10 primary series 2 ) two dose PCV13 ( Arm E ) three dose PCV10 ( Arm A+B ) primary series . A non-inferiority margin 10 % difference absolute risk ( Arm A+B minus Arm C Arm E ) , use regulatory authority , deem clinically significant . The Farrington-Manning ( 1990 ) method use sample size/power estimation , assume one-sided 5 % type I error . If alternative hypothesis non-inferiority accept least 7 10 serotypes , overall non-inferiority declare . The power test individual serotype hypothesis calculate use PASS Software 2002 . The power reject overall null hypothesis estimate simulation , use tailor-made simulation program write implementation Stata 10,000 replication . A sample size 1200 result &gt; 99 % power reject overall null hypothesis two study question , allow 5 % loss follow-up four week post-primary series . An additional 200 participant age 18 month ( Arm G ) recruit time participant Arms A-F reach 18 month age , bring total sample size trial 1400 participant .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Aged 2 month 2 month plus 2 week ( Arms AF ) age 18 month 18 month plus 2 week ( Arm G ) No significant maternal perinatal history Born 36 week gestation Written sign inform consent parent/legal guardian Lives within approximately 30 minute commune health centre Family anticipate live study area next 22 month ( Arms AF ) 6 month ( Arm G ) Has receive three dos either Infanrixhexa Quinvaxem infancy ( Arm G ) Known allergy component vaccine Allergic reaction anaphylactic reaction previous vaccine Known immunodeficiency disorder Known HIVinfected mother Known thrombocytopenia coagulation disorder On immunosuppressive medication Administration plan administration immunoglobulin blood product since birth Severe birth defect require ongoing medical care Chronic progressive disease Seizure disorder History invasive pneumococcal , meningococcal Haemophilus influenzae type b disease , tetanus , measles , pertussis diphtheria infection Receipt 2 month vaccine EPI program ( Arms AF ) receipt PCV ( Arm G ) Family plan give infant Quinvaxem oral polio vaccine ( Arms AF )</criteria>
	<gender>All</gender>
	<minimum_age>60 Days</minimum_age>
	<maximum_age>74 Days</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>10-valent pneumococcal vaccine</keyword>
	<keyword>13-valent pneumococcal vaccine</keyword>
	<keyword>Immunization Schedule</keyword>
	<keyword>Public Health</keyword>
</DOC>